Sepsis is the devastating result of a complex and dysregulated host response to an infection. It leads to an imbalance between pro- and anti-inflammatory mechanisms and predisposes to the development of multiple organ dysfunction syndrome (MODS). Endotoxin is recognized as a major trigger of the immune response leading to pro- and anti-inflammatory cytokine release, activation of the coagulation cascade, vasoplegic shock, and multiple organ dysfunction syndrome. A beneficial effect could be achieved through extracorporeal adsorption of circulating endotoxins in the blood as adjunctive treatment for unresponsive endotoxic shock. However, the precise clinical indication for its initiation is widely debated in the literature. Similar to the source control, microbiological cultures and antibiotics administration, endotoxin activity assay evaluation at regular intervals, and the targeted use of PMX-B hemoperfusion could be lifesaving and adequate within the golden hour for the diagnosis and treatment of endotoxic shock.

**KEYWORDS**
endotoxic shock, hemoperfusion, sequential extracorporeal therapy
is a cartridge containing polymyxin B (PMX-B) immobilized on polystyrene fibers conceived for binding and neutralizing endotoxins from patients’ blood through direct hemoperfusion. Beyond the pathophysiological rationale of the use of PMX-B hemoperfusion (PMX-B HP) for endotoxin removal, the precise clinical indication for its initiation is widely debated in the literature. According to the most updated evidence available from large randomized trials, septic shock patients with MODS score >9 and endotoxin activity assay (EAA) level ranging from 0.6 to 0.9 are those who may benefit the most from PMX-B HP treatment in terms of improvement of survival.5–7 Although there is little evidence supporting the efficacy of PMX-B HP treatment in a selected population with endotoxic shock, the use of PMX-B HP is challenged by a series of trials that show no benefit8 to support the routine use of PMX-B HP to treat patients with sepsis or septic shock.

Apart from the general agreement to personalized indications for this complementary therapy, an appropriate timing indication for its initiation has not yet been proposed.9 Similar to continuous renal replacement therapy (CRRT) performed to counteract acute kidney injury (AKI), physicians should be aware of the effects that an untimely start of PMX-B HP may have in patients with severe endotoxic shock, particularly for Gram-negative sustained sepsis with severe bacteremia, where circulating endotoxin increases due to bactericidal antimicrobial therapy. In this condition, endotoxin neutralization by PMX-B HP therapy might prevent or reduce the physiological (mainly hemodynamic) derangement typically observed during endotoxic shock. The underestimation of this concept could lead to a late, useless, and futile treatment. We believe that, similarly to the source control, microbiological cultures and antibiotics administration, EAA evaluation at regular intervals, and the targeted use of PMX-B HP could be lifesaving, and adequate within the golden hour for the diagnosis and treatment of endotoxic shock (Figure 1A). Also, we strongly suggest maintaining CRRT after treatment with PMX-B HP when AKI concomitantly occurs, and renal replacement support is needed. In these conditions, highly adsorptive hemodiafilters can be considered. For instance, oXiris (AN69ST) is an AN69 membrane with PEI surface coating and immobilized heparin able to unselectively absorb endotoxin and pro- and anti-inflammatory cytokines.10

In summary, the first therapeutic approach in unresponsive endotoxic shock is represented by PMX-B HP, followed by targeted CRRT, as needed, and then scheduling the second session of PMX-HP 18–24 hours after the first one (Figure 1A).

According to our experience and clinical practice, the early phase of hemodynamic instability (vasoactive inotropic score [VIS] 10 < x < 30) during endotoxemia is usually associated with a slight decrease in renal function (kidney disease improving global outcomes [KDIGO] stages 1–2), biomarkers positivity and with an EAA level of 0.3 < x < 0.6. However, several concerns might be raised on the delayed approach of extracorporeal endotoxin removal in these situations. In particular, a rapid increase in endotoxin levels should be expected, particularly for patients with Gram-negative

**FIGURE 1** Flowchart for endotoxin shock management and therapeutic targets
sustained sepsis, due to endotoxin release during bactericidal treatment. Research and clinical protocols should consider an assessment of EAA at regular intervals to identify this rapid endotoxin increase.

Based on our experience, we strongly suggest to start extracorporeal endotoxin removal within 4 hours after source control and starting antibiotic therapy (Figure 1A). An over-time assessment of EAA should be performed in these cases. The further and evident worsening of the renal function, as well as the increase in vasoactive support and a progressive increase in EAA, should corroborate the extracorporeal endotoxin removal initiation. However, an extracorporeal approach confined to patients with severe unresponsive shock (VIS >35 and sequential organ failure assessment score (SOFA) >15) and/or with a high level of EAA (higher than 0.9) should be carefully evaluated, particularly considering the potential futility of this expensive but efficient treatment if used improperly.

Three stages of a “golden hour” might be thus recognized in which the patient with a high risk of endotoxic shock might probably benefit most from endotoxin extracorporeal removal.

The timing becomes a crucial factor in the management of sepsis and the consequent MODS. Based on accurate monitoring and biological markers, an adjust prescription and appropriate delivery of what we defined sequential extracorporeal therapy in sepsis (SETS) might be guaranteed (Figure 1B).

In the early phase, just after source control, PMX-B HP can be the treatment of choice, followed by other extracorporeal blood purification therapies. When organ failure develops, extracorporeal therapies may become a broad spectrum support replacing or supporting the function of several organs such as heart, kidney, liver, and lungs. This is the rationale of extracorporeal organ support (ECOS), a new form of therapy in MODS.

In a comprehensive approach to the endotoxic shock treatment, the evaluation of kidney function, vasopressor requirements, and EAA levels with source control and antibiotic therapy based on the time from sepsis diagnosis, may have a role to personalize the treatment for each specific patient. The dynamic monitoring and prescription could further refine the treatment personalization adequately responding to the criteria of precision medicine. Thus, not only a specific treatment could be provided for every single patient, but even a more specific treatment shall be provided for every moment that patient has a particular need during his/her ICU stay.

ETHICAL APPROVAL AND CONSENT TO PARTICIPATE

This article does not contain any studies with human participants or animals performed by the author.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare related to this manuscript.

AUTHOR CONTRIBUTIONS

All authors contributed equally to the writing of this editorial. All authors read and approved the final manuscript.

ORCID

Silvia De Rosa https://orcid.org/0000-0001-8987-4596

REFERENCES

1. Rittirsch D, Redl H, Huber-Lang M. Role of complement in multi-organ failure. Clin Dev Immunol. 2012;2012:962927.

2. Eng RH, Smith SM, Fan-Havard P, Ogbara T. Effect of antibiotics on endotoxin release from gram-negative bacteria. Diagn Microbiol Infect Dis. 1993;16(3):185–9.

3. Grunfeld C, Feingold KR. Endotoxin in the gut and chylomicrons: translocation or transportation? J Lipid Res. 2009;50(1):1–2.

4. Holzheimer RG. Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother. 2001;13(sup4):159–72.

5. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445–52.

6. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The UPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials. 2014;11(15):218.

7. Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxia: a post hoc analysis of the UPHRATES trial. Intensive Care Med. 2018;44(12):2205–12.

8. Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018;44(2):167–78.

9. Ankawi G, Neri M, Zhang J, Breglia A, Ricci Z, Ronco C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Crit Care. 2018;22(1):262.

10. Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018;6(1):12.

11. Husain-Syed F, Ricci Z, Brodie D, Vincent JL, Ranieri VM, Slutsky AS, et al. Extracorporeal organ support (ECOS) in critical illness and acute kidney injury: from native to artificial organ crosstalk. Intensive Care Med. 2018;44(9):1447–59.

How to cite this article: De Rosa S, Villa G, Ronco C. The golden hour of polymyxin B hemoperfusion in endotoxic shock: The basis for sequential extracorporeal therapy in sepsis. Artif Organs. 2020;44:184–186. https://doi.org/10.1111/aor.13550